June 10, 2019 / 4:43 PM / 6 days ago

BRIEF-FDA Approves First Chemoimmunotherapy Regimen For Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

June 10 (Reuters) - FDA:

* FDA APPROVES FIRST CHEMOIMMUNOTHERAPY REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

* FDA SAYS GRANTED APPROVAL OF POLIVY TO GENENTECH Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below